Understanding drug hypersensitivity: What to look for when prescribing abacavir

AIDS Reader

Volumn 11, Issue 12, 2001, Pages 620-622

  Hetherington, S ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Abacavir; Adverse events; HIV; Hypersensitivity reaction; Nucleoside reverse transcriptase inhibitors

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIHISTAMINIC AGENT; ANTIRETROVIRUS AGENT; CORTICOSTEROID; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ANAMNESIS; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC APPROACH ROUTE; DRUG APPROVAL; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG PACKAGING; DRUG WITHDRAWAL; FATALITY; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LETHARGY; MYALGIA; NAUSEA; PATIENT EDUCATION; PRESCRIPTION; STEROID THERAPY; VOMITING;

DIDEOXYNUCLEOSIDES; DRUG HYPERSENSITIVITY; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0035669917     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Risk factor analysis for hypersensitivity reactions to abacavir
2. Comparison of symptoms of influenza A infection with abacavir-associated hypersensitivity reaction
3. Interruptions in abacavir dosing are not associated with increased risk of hypersensitivity in the HEART (NZT 4006) Study